Russell B Richerson

Title: Russell B. Richerson: Innovator in Methotrexate Metabolite Detection

Introduction

Russell B. Richerson is a notable inventor based in Tucson, AZ (US). He has made significant contributions to the field of biochemistry, particularly in the detection and quantification of methotrexate metabolites. With a total of 2 patents, his work has implications for improving patient care in methotrexate therapy.

Latest Patents

Richerson's latest patents include innovative methods for quantifying methotrexate metabolites. The first patent, titled "Methods of quantifying methotrexate metabolites," provides a method for efficiently converting methotrexate polyglutamates to methotrexate in a cellular extract. This is achieved by contacting the cellular extract with gamma glutamyl hydrolase under conditions suitable for efficient conversion. The second patent, "Methods for direct detection of individual methotrexate metabolites," outlines a method for determining the level of a methotrexate polyglutamate (MTXPG) in a cellular extract. This involves resolving at least one MTXPG in a cellular extract obtained from a human undergoing methotrexate therapy and detecting the resolved MTXPG to determine its level.

Career Highlights

Throughout his career, Richerson has worked with prominent companies in the biotechnology sector. He has been associated with Prometheus Laboratories Inc. and Cypress Bioscience, Inc., where he has contributed to advancements in medical research and product development.

Collaborations

Richerson has collaborated with various professionals in his field, including Thierry Dervieux, enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Russell B. Richerson's innovative work in the detection and quantification of methotrexate metabolites showcases his commitment to advancing medical science. His patents reflect a significant contribution to improving therapeutic outcomes for patients undergoing methotrexate therapy.